Cyclophosphamide + IRX-2 + Nivolumab

Phase 1Withdrawn

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma

Conditions

Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Trial Timeline

Jul 1, 2020 → Jan 31, 2026

NCT ID

NCT03575234

About Cyclophosphamide + IRX-2 + Nivolumab

Cyclophosphamide + IRX-2 + Nivolumab is a phase 1 stage product being developed by Bristol Myers Squibb for Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03575234. Target conditions include Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03575234	Phase 1	Withdrawn	Jul 1, 2020	Jan 31, 2026	Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma

Competing Products

20 competing products in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Influenza vaccine, split inactivated	Comac Medical	Phase 1	25
CS-8958 + CS-8958 + oseltamivir phosphate	Daiichi Sankyo	Phase 3	77
GSK1265744 30mg + Placebo + GSK1265744 5mg	Shionogi	Phase 2	52
Dolutegravir	Shionogi	Phase 3	77
GSK1349572 + efavirenz	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mg	Shionogi	Phase 1	33
GSK1349572 (dolutegravir) + raltegravir	Shionogi	Phase 3	77
Ortho-Cyclen + Dolutegravir + Placebo	Shionogi	Phase 1	33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
dolutegravir	Shionogi	Phase 3	77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo	Shionogi	Phase 3	77
GSK1349572 + Efavirenz	Shionogi	Phase 1	33
GSK1349572	Shionogi	Phase 1	33
GSK1349572 + Placebo	Shionogi	Phase 2	52
Dolutegravir + Methadone	Shionogi	Phase 1	33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir Placebo	Shionogi	Phase 3	77
GSK1349572 + Rifampin + Rifabutin	Shionogi	Phase 1	33
DTG + BCV + TVR	Shionogi	Phase 1	33

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved